• Immutep will present survival data from two trials of eftilagimod alfa in combination with Keytruda at international congresses in November and December 2026.
• EFTISARC-NEO Phase II survival results will be presented at CTOS on Nov. 19, covering treatment with radiotherapy before surgery for resectable soft-tissue sarcoma.
• TACTI-003 Part B final overall survival results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.
• The latter trial evaluates first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in patients with PD-L1-negative tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.